Quality IHC testing: post-analytical phase
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Length: 03:56
Dr Wilko Weichert explains how to ensure quality PD-L1 immunohistochemistry testing in the post-analytical phase. Please see the Summary of Product Characteristics and Risk Minimisation Materials for KEYTRUDA® (pembrolizumab) before making any prescribing decisions and for further information around PD-L1 testing.
to keep updated with the latest education materials in PD-L1 testing
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
